PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

Similar documents
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Study Centers: This study was conducted in 2 centers in Italy.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Clinical Study Synopsis for Public Disclosure

Study No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

Clinical Trial Results Summary Study EN

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Clinical Study Synopsis for Public Disclosure

Subjects from the Safety Population who had GSK PK parameter estimates from any portion of the study. Cohort 1 (N=8)

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Japanese, Korean and Chinese subjects had also lived outside their respective countries for less than 10 years.

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

Study No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis for Public Disclosure

PUBLIC ASSESSMENT REPORT Scientific Discussion

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

SYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22

Clinical Study Synopsis

Sponsor: Sanofi Drug substance(s): SAR342434

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Sponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)

Clinical Study Synopsis for Public Disclosure

PFIZER INC. Study Initiation Date: 15 June 1995; Completion Date: 22 April 1996

Product: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.

Clinical Study Synopsis

PFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

Results. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study

BRL /RSD-101C0D/1/CPMS-704. Report Synopsis

HM2008/00566/00. study and to obtain clinical experience with the use of this drug. Primary Outcome/Efficacy Variable(s): <Pharmacokinetics>

(For National Authority Use Only) Name of Study Drug: to Part of Dossier:

Clinical Study Synopsis

Clinical Study Synopsis

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)

Final Report (Amendment 1) April 11, 2006 Page 4 of 50

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

090177e182b31c5d\0.1\Draft\Versioned On:16-Dec :12

Sponsor: Sanofi Drug substance(s): GZ316455

Clinical Study Synopsis

Clinical Study Synopsis

Principal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods:

Hydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109

Referring to Part IV of the Dossier

Clinical Study Synopsis

PFIZER INC. Study Initiation Date and Completion Dates: 09 March 2000 to 09 August 2001.

SYNOPSIS. Issue Date: 31 July 2013

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not

Pentoxifylline Extended-Release Tablets 400 mg

Clinical Study Synopsis for Public Disclosure

Clinical Study Synopsis

Pharmacokinetics, pharmacodynamics and pharmacogenetics of aripiprazole and olanzapine in healthy subjects

A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.

Oral Soluble Film Products for Epilepsy: Clobazam (COSF) and Diazepam (DBSF)

INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

PFIZER INC. Study Initiation Date and Completion Dates: Information not available (Date of Statistical Report: 16 May 2004)

PFIZER INC. Study Centres: A total of 8 centres in France took part in the study.

PFIZER INC. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Cerebyx / Fosphenytoin Sodium

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:

Clinical Study Report AI Final 28 Feb Volume: Page:

BRL /RSD-101RLL/1/CPMS-716. Report Synopsis

Study No: Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods: Sample Size

Clinical Study Synopsis

SINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF MOXDUO, A DUAL-OPIOID FORMULATION CONTAINING A FIXED RATIO OF MORPHINE AND OXYCODONE

These results are supplied for informational purposes only.

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:

Pharmacokinetic Interaction Between Norgestimate/Ethinyl Estradiol and EVG/COBI/FTC/TDF Single Tablet Regimen

PhRMA Clinical Study Synopsis Protocol CTN / (A /A ) 21 August 2006 Final PFIZER INC.

Principal Investigator: Robert J. Jones, MD, Beatson Cancer Center, 1053 Great Western Road, Glasgow; United Kingdom

Clinical Study Synopsis

Clinical Study Synopsis for Public Disclosure

The pharmacokinetics and dose proportionality of cilazapril

Individual Study Table Referring to Part of the Dossier. Volume:

SYNOPSIS (FOR NATIONAL AUTHORITY USE ONLY) INDIVIDUAL STUDY TABLE REFERRING TO PART OF THE DOSSIER

Clinical Study Synopsis

Principal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA

BRL /RSD-101C0F/1/CPMS-716. Report Synopsis

PFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: This drug is not marketed in the United States.

Treatment A Placebo to match COREG CR 20 mg OD + Lisinopril 10 mg OD (Days 1-7) Placebo to match COREG CR 40 mg OD + Lisinopril 10 mg OD (Days 8-14)

Transcription:

PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography. PROPRIETARY DRUG NAME/INN: Xanax XR / Alprazolam THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI PROTOCOL NO.: A6131003 PROTOCOL TITLE: Comparison of the Pharmacokinetics of an Extended Release Formulation of Alprazolam (Xanax XR ) in Healthy Normal Adolescent and Adult Volunteers Study Center(s): One (1) center in the United States Study Initiation and Completion Dates: 23 October 2003 to 15 November 2003 Phase of Development: Phase 1 Study Objective(s): The purpose of this study was to estimate (1) the pharmacokinetics and (2) the safety and tolerability of single doses of alprazolam extended release in adolescent and adult healthy volunteers. METHODS Study Design: This was a randomized, open-label, single-dose, 2-period crossover study. Eligible subjects received single doses of alprazolam extended release 1 mg or 3 mg tablets in a crossover fashion. Subjects underwent a 7-day washout period between doses. Number of Patients (planned and analyzed): Planned: 24 healthy volunteers (12 adolescents and 12 adults) Analyzed: 24 healthy volunteers (12 adolescents and 12 adults) Diagnosis and Main Criteria for Inclusion: Health status was determined by a detailed medical history, full physical examination (including blood pressure [BP] and heart rate [HR] measurement), 12-lead electrocardiogram (ECG), and clinical laboratory tests. The adolescent volunteers were comprised of males and females between the ages of 13 and 17 years of age, inclusive. Adult volunteers were comprised of males and females between the ages of 20 and 45 years of age, inclusive. Study Treatment: Alprazolam extended release 1 mg or 3 mg tablets for oral administration Efficacy Evaluations: No efficacy evaluations were performed in this study. Pharmacokinetic Evaluations: Blood samples were collected at 0 (just prior to dosing), 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 hours postdose on study Day 1 of each study period. The following

pharmacokinetic (PK) parameters were determined for alprazolam: area under the curve (AUC) from time 0 hours to the final measurable time point (AUC(0-t)), area under the curve extrapolated to infinity (AUC(0- )), maximum plasma concentration (Cmax), time-to-maximum plasma concentration or first occurrence of Cmax (Tmax), and terminal elimination half-life (t½). AUC(0-t), Cmax, and Tmax were determined for the 2 major metabolites α-hydroxy-alprazolam and 4-hydroxy-alprazolam. Safety Evaluations: Safety assessments included clinical laboratory tests, vital signs, and adverse event monitoring. Statistical Methods: Log-transformed dose-normalized AUC(0- ) and Cmax were analyzed by mixed effects analysis of variance (ANOVA), with age-group, dose, and period effects and interaction terms, period*dose and age-group*dose, considered fixed and subject considered random. For the comparison between the adults and adolescents, 95% confidence intervals on the adjusted mean ratio of AUC(0-t) and AUC(0- ) for the adolescents vs the adults was computed. For the dose comparisons with each group, the 90% confidence interval on the dose adjusted mean ratio of AUC(0-t), and AUC(0- ) for the 3 mg vs the 1 mg dose was compared to the equivalence limits (80, 125%). An exploratory regression analysis was performed for the adolescent subset to assess the effects of age, weight, and sex on the endpoints AUC(0- ) and Cmax. For each endpoint, the fixed independent factors were dose, age, weight, and sex; subject was a random effect. Vital signs were summarized using descriptive statistics (means and change from baseline). RESULTS Subject Disposition and Demography: A total of 24 healthy volunteers were recruited to this study - 12 adolescents and 12 adults. All subjects completed the study. There were 5 male and 7 female adolescent subjects and 4 male and 8 female adults aged between 13 and 44 years. Twenty-three of the 24 volunteers were white and one was black. Efficacy Results: There were no efficacy evaluations performed in this study. Pharmacokinetic Results: The mean pharmacokinetic profiles of alprazolam, α-hydroxyalprazolam, and 4-hydroxy-alprazolam were similar in adolescent and adult subjects after administration of 1 mg and 3 mg alprazolam (Table S1). Protocol A6131003 / Page 2 of 5

Table S1 Arithmetic Means (SD) for Cmax, Tmax, AUC, and T½ N Cmax (ng/ml) Tmax* (hr) AUC(0- ) T½ (hr) (ng hr/ml) Alprazolam Adolescent, 1 mg 11 9.07 (1.4) 9.82 (2.8) 298.55 (67.8) 15.36 (3.6) Adult, 1 mg 9 7.83 (1.4) 8.33 (3.3) 252.14 (66.9) 15.62 (3.1) Adolescent, 3 mg 11 24.61 (4.7) 10.00 (5.8) 832.66 (144.3) 14.45 (3.6) Adult, 3 mg 9 23.63 (4.4) 9.00 (4.1) 762.78 (243.5) 15.62 (4.7) 4OH-Alprazolam Adolescent, 1 mg 11 0.90 (0.6) 11.64 (0.8) 34.91 (15.7) 24.08 (11.0) Adult, 1 mg 9 0.90 (0.5) 12.00 (5.0) 38.59 (18.5) 21.41 (10.8) Adolescent, 3 mg 11 2.69 (1.5) 14.67 (5.7) 105.28 (56.7) 16.64 (6.3) Adult, 3 mg 9 2.58 (1.5) 11.78 (5.3) 94.57 (55.5) 19.49 (3.4) αoh-alprazolam Adolescent, 1 mg 11 0.26 (0.2) 10.67 (2.8) 4.95 (5.4) 25.00 (6.5) Adult, 1 mg 9 0.18 (0.2) 13.67 (5.1) 2.21 (2.9) NA Adolescent, 3 mg 11 0.96 (0.4) 12.50 (3.7) 27.59 (9.3) 20.65 (10.0) Adult, 3 mg 9 0.67 (0.2) 13.56 (6.5) 17.76 (7.6) 23.12 (11.8) *Median (range); NA= Not Assessed. Between-age-groups comparison (adolescent to adults) of 1 mg and 3 mg alprazolam were made separately and as combined doses (Table S2). Dose-proportionality comparisons of 3 mg to 1 mg of alprazolam were made within the adult group and within the adolescent group (Table S3). Table S2 Summary of Statistical Analyses of Alprazolam PK Parameters for Alprazolam Extended Release 1 mg, Alprazolam Extended Release 3 mg, and Doses Combined: Between-Age-Groups Comparison Parameter Comparison (Test/Reference) Ratio (%) 95% CI Between Group: Adolescent (Test) vs Adult (Reference) AUC(0- ) (ng h/ml) Adolescent, 1 mg/adult, 1 mg 119 94, 150 Adolescent, 3 mg/adult, 3 mg 112 88, 141 Adolescent, Combined/Adult, Combined 115 93, 143 Cmax (ng/ml) Adolescent, 1 mg/adult, 1 mg 116 99, 137 Adolescent, 3 mg/adult, 3 mg 106 90, 125 Adolescent, Combined/Adult, Combined 111 95, 129 CI = confidence interval Table S3 Summary of Statistical Analyses of Alprazolam PK Parameters for Adolescents and Adults: Within-Age-Groups Comparison Parameter Comparison (Test/Reference) Ratio (%) 90% CI Adolescent Within Group AUC(0- ) (ng h/ml) 3 mg / 1 mg 94 86, 103 Cmax (ng/ml) 3 mg / 1 mg 89 83, 95 Adult Within Group AUC(0- ) (ng h/ml) 3 mg / 1 mg 100 86, 116 Cmax (ng/ml) 3 mg / 1 mg 97 88, 107 CI = confidence interval Exploratory Regression Analysis for Adolescent Subjects: The weight and dose effects for lncmax PK parameter were found to be statistically significant (p<0.0337). There were no Protocol A6131003 / Page 3 of 5

significant age and gender effects for lnauc(0- ) and lncmax PK parameters (p>0.4841). For lnauc(0- ), there were no significant weight and dose effects (p>0.2495). Table S4 presents the predicted mean Cmax for age, weight and gender. Table S4 Predicted Mean Cmax for Age and Weight Dose Age Weight Gender Predicted Cmax 1 mg 13 50 Male 11.621 Female 11.044 85 Male 7.731 Female 7.348 17 50 Male 10.811 Female 10.275 85 Male 7.193 Female 6.836 3 mg 13 50 Male 10.375 Female 9.861 85 Male 6.903 Female 6.560 17 50 Male 9.653 Female 9.174 85 Male 6.422 Female 6.103 Safety Results: There were a total of 31 treatment-emergent adverse events (AEs) reported by 20 subjects. All AEs were either mild (N=13) or moderate (N=18) in severity. All treatment emergent adverse events are presented in Table S5, below. Table S5 Treatment-Emergent Adverse Events Alprazolam Extented Release Body System / COSTART Preferred Term Adolescents 1 mg Adults 1 mg Adolescents 3 mg Adults 3 mg Body as a Whole 0 1 2 1 Headache 0 1 1 1 Abdominal pain 0 0 1 0 Digestive 1 0 0 0 Nausea 1 0 0 0 Nervous 4 3 11 6 Somnolence 4 3 10 6 Dizziness 0 0 1 0 Respiratory 0 0 1 0 Hiccups 0 0 1 0 Skin and Appendages 0 1 0 0 Rash 0 1 0 0 Total Number of AEs 5 5 14 7 Total Number of Subjects with AEs 4 5 10 7 Total Number of Subjects Exposed 12 12 12 12 Protocol A6131003 / Page 4 of 5

There were no deaths, serious adverse events or discontinuations due to adverse events reported in this study. None of the clinical laboratory parameters or vital signs measurements were of clinical concern. CONCLUSION(S): The AUC(0- ) and Cmax results demonstrate dose proportionality of alprazolam after single 1 mg and 3 mg doses for both adolescents and adults. Mean concentration-time profiles were similar for both groups of subjects. Compared with adults, relative AUC(0- ) and Cmax in adolescents, expressed as ratios of the estimated geometric means for both dose levels, were 115% and 111%, respectively. These differences are thought not to be of clinical relevance. In this study, single-dose administration of 1 mg and 3 mg Alprazolam extended release tablets was safe in both adolescent and adult subjects. Somnolence was noted in a dose-related fashion in both study populations. All cases of somnolence resolved without intervention. Based on a report completed on: 06 October 2004 Protocol A6131003 / Page 5 of 5